417 related articles for article (PubMed ID: 16010427)
1. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
Emura T; Suzuki N; Fujioka A; Ohshimo H; Fukushima M
Int J Oncol; 2005 Aug; 27(2):449-55. PubMed ID: 16010427
[TBL] [Abstract][Full Text] [Related]
2. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K
Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072
[TBL] [Abstract][Full Text] [Related]
3. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
4. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.
Emura T; Nakagawa F; Fujioka A; Ohshimo H; Yokogawa T; Okabe H; Kitazato K
Int J Mol Med; 2004 Feb; 13(2):249-55. PubMed ID: 14719131
[TBL] [Abstract][Full Text] [Related]
5. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors.
Matsushita S; Nitanda T; Furukawa T; Sumizawa T; Tani A; Nishimoto K; Akiba S; Miyadera K; Fukushima M; Yamada Y; Yoshida H; Kanzaki T; Akiyama S
Cancer Res; 1999 Apr; 59(8):1911-6. PubMed ID: 10213500
[TBL] [Abstract][Full Text] [Related]
6. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides.
Fukushima M; Suzuki N; Emura T; Yano S; Kazuno H; Tada Y; Yamada Y; Asao T
Biochem Pharmacol; 2000 May; 59(10):1227-36. PubMed ID: 10736423
[TBL] [Abstract][Full Text] [Related]
7. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
8. [Up-regulation of thymidine phosphorylase and anti-angiogenesis by interferon alpha in human hepatocellular carcinoma cell line and xenograft].
Xiao YS; Zhou J; Tang ZY; Fan J; Wu ZQ; Liu YK; Ye SL; Shen ZZ; Xue Q; Zhao Y
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3205-9. PubMed ID: 16405841
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor.
Tsuchiya H; Kuwata K; Nagayama S; Yamashita K; Kamiya H; Harashima H
Drug Metab Pharmacokinet; 2004 Jun; 19(3):206-15. PubMed ID: 15499188
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed.
Graham-Cole CL; Thomas HD; Taylor GA; Newell DR; Melton RG; Hesp R; Boddy AV
Cancer Chemother Pharmacol; 2007 Feb; 59(2):197-206. PubMed ID: 16721548
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitization by thymidine phosphorylase inhibitor in thymidine phosphorylase negative and overexpressing bladder cancer cell lines.
El-Naggar M; Ebbing E; Bijnsdorp I; van den Berg J; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):413-21. PubMed ID: 24940699
[TBL] [Abstract][Full Text] [Related]
13. Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo.
Tsukagoshi S; Saga Y; Suzuki N; Fujioka A; Nakagawa F; Fukushima M; Suzuki M
Int J Oncol; 2003 May; 22(5):961-7. PubMed ID: 12684660
[TBL] [Abstract][Full Text] [Related]
14. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Temmink OH; Prins HJ; van Gelderop E; Peters GJ
Br J Cancer; 2007 Jan; 96(1):61-6. PubMed ID: 17179993
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 1: discovery of novel orally active inhibitors of human thymidine phosphorylase.
Yano S; Kazuno H; Suzuki N; Emura T; Wierzba K; Yamashita J; Tada Y; Yamada Y; Fukushima M; Asao T
Bioorg Med Chem; 2004 Jul; 12(13):3431-41. PubMed ID: 15186829
[TBL] [Abstract][Full Text] [Related]
16. Suppression of thymidine phosphorylase-mediated angiogenesis and tumor growth by 2-deoxy-L-ribose.
Uchimiya H; Furukawa T; Okamoto M; Nakajima Y; Matsushita S; Ikeda R; Gotanda T; Haraguchi M; Sumizawa T; Ono M; Kuwano M; Kanzaki T; Akiyama S
Cancer Res; 2002 May; 62(10):2834-9. PubMed ID: 12019161
[TBL] [Abstract][Full Text] [Related]
17. [Influence of the thymidine phosphorylase (platelet-derived endothelial cell growth factor) on tumor angiogenesis. Catalytic activity of enzyme inhibitors].
Miszczak-Zaborska E; Smolarek M; Bartkowiak J
Postepy Biochem; 2010; 56(1):61-6. PubMed ID: 20499682
[TBL] [Abstract][Full Text] [Related]
18. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
20. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
